Comparing the activity of multiple sclerosis (MS) at the minute and at 20 minutes of gadolinium application in magnetic resonance imaging (MRI) of the brain?

Christina Saldívar-Uribe; Mario Alberto de la Portilla-Villanueva; Alberto Esau-Mendoza-García

2017, Number 1

<< Back Next >>

Gac Med Mex 2017; 153 (1)

Comparing the activity of multiple sclerosis (MS) at the minute and at 20 minutes of gadolinium application in magnetic resonance imaging (MRI) of the brain?

Saldívar-Uribe C, de la Portilla-Villanueva MA, Esau-Mendoza-García A

Full text

How to cite this article

Language: Spanish
References: 18
Page: 88-91
PDF size: 59.69 Kb.

ABSTRACT

The aim was to compare active disease in patients diagnosed with multiple sclerosis, brain by MRI after gadolinium application at one minute and 20 minutes. A longitudinal, prospective, observational, analytical and comparative study was conducted in 18 patients over 18 years of age diagnosed with multiple sclerosis (MS). An analysis was made for each patient, watching for inflammatory activity in MS lesions, comparing the results to one minute and 20 minutes after the application of gadolinium. For the descriptive analysis, absolute frequencies and percentages were used, as well as means and standard deviations or medians with ranges for the inferential analysis comparing the presence or absence of enhancement in lesions at one minute and 20 minutes; the exact probability test used was Fisher. Finally, the results were analyzed, looking at the gender distribution: 14 (77.8%) were female. The average age was 36.2 ± 9.5 years, with a minimum age of 18 years and a maximum of 55 years; four patients (22.2%) presented further highlight active lesions at 20 minutes, and two patients (11.1%) presented enhancement at one minute. Concluding that MRI in the diagnosis of MS is very important for the detection of activity in lesions caused by the disease, it is evident that the optimum time for evaluation of postcontrast sequences is 20 minutes.

REFERENCES

O’Connor P. Key issues in the diagnosis and treatment of multiple sclerosis. Neurology. 2002;59(Suppl 3):33.
McDonald WI, Compston A, Edan G, et al. Recommended diagnosis criteria for multiple sclerosis: guidelines from the International Panel Diagnosis of Multiple Sclerosis. Ann Neurol. 2001;50:121-7.
Arnold DL, Matthews PM. MRI in the diagnosis and management of multiple sclerosis. Neurology. 2002;58:S23-31.
Confravreux C, Suissa S, Saddier P, et al. Vaccinations and the risk of relapse in multiple sclerosis. N Engl J Med. 2001;344:319-26.
Frohman E. Multiple sclerosis. Med Clin North Am. 2003;87:867-97.
Halfpenny C, Benn T, Scolding N. Cell transplantation, myelin repair and multiple sclerosis. Lancet Neurol. 2002;1:31-40.
Sawcer S, Franklin RJ, Ban M. Multiple sclerosis genetics. Lancet Neurol. 2014;13:700-9.
Rovaris M, Gass A, Bammer R, et al. Diffusion MRI in multiple sclerosis. Neurology. 2005;65:1526-32.
Lublin FD. The diagnosis of multiple sclerosis. Curr Opin Neurol. 2002; 15:253-6.
Miller DH, Barkhof F, Frank JA, et al. Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain. 2002;125:1676-95.
Polman C, Uitdehaag B. New and emerging treatment options for multiple sclerosis. Lancet Neurol. 2003;2:563-6.
Pons-Porrata LM, De la Cruz A, Álvarez-Cobas I, Daudimot-Gutiérrez Y, Salomon-López J. Caracterización del uso de gadolinio en pacientes con indicación de resonancia magnética. Medisan. 2012;16: 498-503.
Rovira A. Resonancia magnética en el diagnóstico de la esclerosis múltiple. Radiología. 2001;43:465-76.
Silver NC, Good CD, Barker GJ, et al. Sensitivity of contrast enhanced MRI in multiple sclerosis. Effects of gadolinium dose, magnetization transfer contrast and delayed imaging. Brain. 1997;120:1149-61.
Kermode AG, Thompson AJ, MacManus DG, et al. Heterogeneity of blood-brain barrier changes in multiple sclerosis. Neurology. 1990;40: 1526-632.
Miller DH, Barkhof F, Nauta JP. Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis. Brain. 1993;116:1077-94.
Lovblad K-O, Anzalone N, Dorfler A, et al. MR imaging in multiple sclerosis: review and recommendations for current practice. Am J Neuroradiol. 2010;31:983-9.
Uysal E, Erturk SM, Yildirim H, Seleker F, Basak M. Sensitivity of immediate and delayed gadolinium-enhanced MRI after injection of 0.5 M and 1.0 M gadolinium chelates for detecting multiple sclerosis lesions. AJR Am J Roentgenol. 2007;188:697-702.